Imprimis Pharmaceuticals Inc (IMMY)

4.19
0.20 5.00
NASDAQ : Health Care
Prev Close 3.99
Open 4.02
Day Low/High 4.02 / 4.39
52 Wk Low/High 3.34 / 8.79
Volume 687.65K
Avg Volume 131.50K
Exchange NASDAQ
Shares Outstanding 18.63M
Market Cap 71.72M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Imprimis Pharmaceuticals Begins Dispensing From FDA-Registered 503B Outsourcing Facility

Imprimis Pharmaceuticals Begins Dispensing From FDA-Registered 503B Outsourcing Facility

Improved efficiencies and additional revenue opportunities expected for Imprimis' ophthalmic portfolio

Imprimis Pharmaceuticals And FocusScript Partner To Exclusively Offer The Correct Compound™ Program

Imprimis Pharmaceuticals And FocusScript Partner To Exclusively Offer The Correct Compound™ Program

The Correct Compound™ program combines the cost savings of the Imprimis Cares® portfolio of compounded medications with FocusScript's accredited and credentialed network, proprietary Compound Drug Formulation Logic program (CDF-Logic™) and world-class suite of prescription drug processing tools

Imprimis Pharmaceuticals Ranked 12 On Deloitte's 2016 Technology Fast 500™ List Of Fastest Growing Companies In North America

Imprimis Pharmaceuticals Ranked 12 On Deloitte's 2016 Technology Fast 500™ List Of Fastest Growing Companies In North America

Imprimis attributes significant growth to innovative business model and growing demand for its Imprimis Cares® portfolio of cost-effective compounded medications

Imprimis Pharmaceuticals Signs Agreement With Specialty Pharmacy Division Of One Of The Nation's Largest Pharmacy Benefit Managers

Imprimis Pharmaceuticals Signs Agreement With Specialty Pharmacy Division Of One Of The Nation's Largest Pharmacy Benefit Managers

Agreement to supply Imprimis Cares complete formulary streamlines the drug dispensing model, creating a new solution to lower drug costs for patients, physicians, health insurance plans and employers

Imprimis Pharmaceuticals To Host Its Third Quarter 2016 Financial Report

Imprimis Pharmaceuticals To Host Its Third Quarter 2016 Financial Report

Conference Call and Webcast on November 14, 2016 at 4:30 p.m. EST

Imprimis Pharmaceuticals Registers Its New Jersey Facility With The FDA As An Outsourcing Facility

Imprimis Pharmaceuticals Registers Its New Jersey Facility With The FDA As An Outsourcing Facility

Improved efficiencies and additional revenue opportunities expected for Imprimis' Proprietary Dropless Therapy® Injectable and LessDrops® Topical Formulations

Imprimis' Dropless Therapy Shows Significant Advantages In A Large Peer-Reviewed Study

Imprimis' Dropless Therapy Shows Significant Advantages In A Large Peer-Reviewed Study

Compounded prophylactic formulation provides benefit for cataract patients following surgery

Imprimis Pharmaceuticals Announces Availability Of Lower-Cost Option For The Treatment Of Lead Poisoning

Imprimis Pharmaceuticals Announces Availability Of Lower-Cost Option For The Treatment Of Lead Poisoning

Imprimis' $495 EDTA calcium disodium injectable formulation provides significant cost savings compared to Valeant's $27,000 drug

Imprimis Pharmaceuticals' Formulations To Be Highlighted At Upcoming Annual Ophthalmology Meeting In Chicago

Imprimis Pharmaceuticals' Formulations To Be Highlighted At Upcoming Annual Ophthalmology Meeting In Chicago

Planned events and sessions will highlight Dropless Therapy®, LessDrops® combination drop therapy and IV-Free MKO Melt conscious sedation formulations

Imprimis Pharmaceuticals' CEO Mark L. Baum To Debate At The Oxford Union Debating Society

Imprimis Pharmaceuticals' CEO Mark L. Baum To Debate At The Oxford Union Debating Society

Baum to argue in favor of the debate motion: "Big Pharma Prioritizes Profits Over Patients"

Imprimis Pharmaceuticals Accelerates Profitability Timeline By Implementing Expense Reduction Program

Imprimis Pharmaceuticals Accelerates Profitability Timeline By Implementing Expense Reduction Program

Cost reduction strategies to improve efficiencies and position company for sustainable growth

Following Congressional Hearing Investigating Mylan And Epi-Pen, Imprimis Pharmaceuticals Founder And CEO Publishes Drug Pricing Monograph

Following Congressional Hearing Investigating Mylan And Epi-Pen, Imprimis Pharmaceuticals Founder And CEO Publishes Drug Pricing Monograph

Safe pharmaceutical compounding can play an invaluable role in resolving the U.S. drug pricing crisis

Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares® Compounded Formulations

Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares® Compounded Formulations

ICAN program designed to facilitate the insurance payment process and substantially reduce or eliminate patient payment challenges

EpiPen Price Relief Could Come From Rivals Before Politicians

EpiPen Price Relief Could Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Imprimis Pharmaceuticals Strengthens Senior Leadership Team With Key Hires In Operations, Quality, Manufacturing And Client Relations

Imprimis Pharmaceuticals Strengthens Senior Leadership Team With Key Hires In Operations, Quality, Manufacturing And Client Relations

Four industry leaders bring significant depth of experience to drive Imprimis' next phase of growth

Imprimis Launches New MaxRx Prescriber Portal™

Imprimis Launches New MaxRx Prescriber Portal™

MaxRx™ software is a key tool to optimize customer experience; Imprimis continues to integrate new processes and systems to scale its business

Peer-Reviewed Study Of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared To Drops

Peer-Reviewed Study Of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared To Drops

Journal of Clinical Ophthalmology reports 'strong patient preference' for Imprimis Pharmaceuticals' Dropless Therapy® formulation

Clinical Study Of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction In Cystoid Macular Edema In Patients Following Cataract Surgery

Clinical Study Of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction In Cystoid Macular Edema In Patients Following Cataract Surgery

Study results presented at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans

Imprimis Pharmaceuticals Announces Plans To Launch IV Free™ Conscious Sedation And New Compounded Triple Drop Formulations At Leading Cataract And Refractive Surgeons Meeting

Imprimis Pharmaceuticals Announces Plans To Launch IV Free™ Conscious Sedation And New Compounded Triple Drop Formulations At Leading Cataract And Refractive Surgeons Meeting

Patent-pending MKO Melt™ sublingual sedation and anesthetic provides surgeons with a new approach for patients undergoing ophthalmic and other outpatient surgical procedures

Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative To Thiola®

Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative To Thiola®

New customizable compounded tiopronin delayed-release formulations may significantly reduce costs and the number of pills cystinuria patients take daily